Innova Captab Ltd Q4 FY25 Results & Concall Highlights: Revenue, Margins & Order Book

Published 6 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹5.4K Cr

Innova Captab aims for a long-term CAGR of 25% revenue growth over the next 3 years. Innova Captab aims for a 25% CAGR revenue growth over the next 3 years.

From Innova Captab Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.

Price

1,088

Market Cap

₹5.4K Cr

P/E Ratio

38.5

How does Innova Captab Ltd rank in Pharmaceuticals & Biotechnology?

Compare Innova Captab Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Innova Captab Ltd — Quarterly revenue & net profit

Revenue Net Profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹448 Cr, net profit ₹38 Cr.

Full financials →

📊 Revenue & Sales Performance

  • Innova Captab aims for a long-term CAGR of 25% revenue growth over the next 3 years.
  • Jammu plant is expected to contribute around INR 400 crores in revenue for FY '26, with initial revenue of INR 36 crores in Q4 FY '25.
  • CDMO business volume growth is estimated around 7%-8% for the full year, slightly better than reported revenue growth of 6%-7%.
  • Sharon business aims to revive and grow positively post-CIRP, focusing on onboarding new customers and products, targeting regulated markets like Europe and Canada.
  • Domestic Branded Generics expect mid-teen growth rates (~12-13%), driven by volume growth, new products, and market penetration.
  • New products and dosage forms from the Jammu plant and R&D facility at Panchkula will accelerate growth.
  • EBITDA and profit margins are expected to improve with increased operations, operating leverage, GST benefits, and product mix improvements.

📈 Profitability & Margins

  • Innova Captab aims for a 25% CAGR revenue growth over the next 3 years.
  • Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) margin is expected to improve due to operating leverage, GST benefits, and operational efficiencies.
  • EBITDA neutral level at INR50-55 crores sales in Jammu plant indicates planned profitability growth.
  • PAT margins improved by 160 basis points to 10.3% in FY '25, with expectations to sustain or improve.
  • The new Jammu plant is poised to contribute INR400 crores revenue in FY '26, enhancing profits.
  • Revival and product expansion in Sharon business expected to drive growth in regulated markets.
  • Overall profit growth is supported by volume expansion, product mix improvement, and efficient resource utilization.

🏗️ Capital Expenditure Plans

  • Innova Captab has commissioned a new facility in Kathua, Jammu, which started commercial operations in January 2025.
  • The company expects the Jammu plant to generate around INR 400 crores in revenue in FY '26.
  • Upcoming R&D facility in Panchkula, Haryana focused on developing generic and complex generic products, including immediate release, super bioavailability capsules, and nano size formulations targeting regulated markets.
  • The Jammu plant includes expansion into acute products, beta-lactam, penem, LVP, respules, and waterfall injection formulations, reflecting strategic product portfolio diversification.
  • Working capital investments have increased to support rising operations and the startup of the Jammu plant, expected to normalize over time.
  • Capital expenditure includes maintenance capex consistent with existing depreciation rates, along with new facility investments to support growth and product innovation.

💰 Fundraising & Capital Structure

The transcript from the earnings call does not mention any current or planned fundraising through debt or equity. Key points related to financing or capital structure include: - No specific discussion on raising funds via debt or equity during the call. - Focus remains on growth through operational revenue, including INR400 crore revenue expected from the new Jammu plant. - Working capital investment increased due to expansion but expected to normalize. - Confident about maintaining a 25% CAGR in revenue growth over the next 3 years without mentioning external fundraising. - Margin improvement targets primarily through operational efficiencies, GST incentives, and economies of scale rather than new capital raise. Overall, no indication of any imminent or planned fundraising activities via debt or equity was shared in the provided transcript.

📋 Order Book & Pipeline

- The management did not explicitly mention a specific current or expected orderbook value during the call. - Confidence was expressed regarding future revenue targets, including a guidance of INR 400 crores incremental revenue from the Jammu plant in FY '26. - The company is maintaining a long-term revenue CAGR target of 25% over the next three years. - Efforts are focused on onboarding new customers and products, especially in regulated markets like Europe and Canada through their Sharon subsidiary. - The Jammu plant, recently commercialized, is expected to contribute significantly to revenue and margin improvement as operations scale. - There is strategic focus on expanding wallet share with existing clients and acquiring new clients in CDMO and regulated market segments. - Overall, the revenue visibility is built on existing customer relationships, new product launches, and capacity expansion in four manufacturing blocks. No direct mention of a quantified pending orderbook was provided.

Key Metrics

Frequently Asked Questions

What were Innova Captab Ltd Q4 FY25 results?

Innova Captab aims for a long-term CAGR of 25% revenue growth over the next 3 years. Innova Captab aims for a 25% CAGR revenue growth over the next 3 years.

What is Innova Captab Ltd share price analysis?

Innova Captab Ltd currently shows a neutral. The stock trades at a P/E of 38.5 with a market cap of ₹5,408 Cr. Investors should review the full earnings analysis for detailed insights.

Is Innova Captab Ltd planning capital expenditure?

Innova Captab has commissioned a new facility in Kathua, Jammu, which started commercial operations in January 2025.

Keep Innova Captab Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.

What Innova Captab's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Biocon (Q4 FY25)

    FY'25 saw a consolidation and transition phase setting up for accelerated growth, with a 10% YoY increase in revenue and 16% YoY growth in core EBITDA (Page…

  • Natural Capsules (Q4 FY25)

    196 crore, implying about Rs. Key concall takeaways from Natural Capsules Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.

  • Laurus Labs (Q4 FY25)

    Capex of around INR1,000 crore planned for FY26 primarily to expand CDMO/CMO capacities, with minimal increase in debt. Key concall takeaways from Laurus Labs…

  • Wockhardt Ltd (Q4 FY25)

    EBITDA growth: Recorded a 67% increase in the last year, with EBITDA margins expanding by 500 basis points from 9% to 14%. Key concall takeaways from Wockhardt…